West Pharmaceutical beats top-line and bottom-line estimates; raises FY26 outlook

West Pharmaceutical Q3 earnings beat estimates on EPS and revenue, raised 2026 guidance, and boosted its dividend.

CryptoAlerta — análise de criptomoedas e mercado em tempo real